| 齐巧娜,许本善,邹梦颖,顾 乡,李延晖,王 欢.黄葵胶囊联合阿魏酸哌嗪片对慢性肾小球肾炎患者肾功能、氧化应激和血清MMP-9、TIMP-1的影响[J].现代生物医学进展英文版,2022,(5):990-993. |
| 黄葵胶囊联合阿魏酸哌嗪片对慢性肾小球肾炎患者肾功能、氧化应激和血清MMP-9、TIMP-1的影响 |
| Effects of Huangkui Capsule Combined with Piperazine Ferulate Tablets on Renal Function, Oxidative Stress and Serum MMP-9 and TIMP-1 in Patients with Chronic Glomerulonephritis |
| Received:August 06, 2021 Revised:August 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.05.039 |
| 中文关键词: 黄葵胶囊 阿魏酸哌嗪片 慢性肾小球肾炎 肾功能 氧化应激 MMP-9 TIMP-1 |
| 英文关键词: Huangkui capsule Piperazine ferulate tablets Chronic glomerulonephritis Renal function Oxidative stress MMP-9 TIMP-1 |
| 基金项目:北京市自然科学基金项目（7092039） |
|
| Hits: 665 |
| Download times: 496 |
| 中文摘要: |
| 摘要 目的：观察黄葵胶囊联合阿魏酸哌嗪片治疗慢性肾小球肾炎患者的应用价值。方法：选择2019年4月~2021年1月期间我院收治的慢性肾小球肾炎患者131例，以双色球随机分组法将患者分为对照组65例（阿魏酸哌嗪片治疗）、实验组66例（黄葵胶囊联合阿魏酸哌嗪片治疗）。对比两组疗效、肾功能[血肌酐（Scr）、尿素氮（BUN）、24 h 尿蛋白定量（24 h-Upr）]、氧化应激[超氧化物歧化酶（SOD）、丙二醛（MDA）]和血清基质金属蛋白酶-9（MMP-9）、基质金属蛋白酶组织抑制因子-1（TIMP-1）水平，记录两组不良反应发生率。结果：与对照组比较，实验组的临床总有效率明显更高（P<0.05）。与对照组相比，实验组治疗3个月后Scr、BUN、24 h-Upr更低（P<0.05）。与对照组相比，实验组治疗3个月后TIMP-1更低，MMP-9更高（P<0.05）。与对照组相比，实验组治疗3个月后MDA更低，SOD更高（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：黄葵胶囊联合阿魏酸哌嗪片治疗慢性肾小球肾炎，可减轻机体氧化应激，调节血清MMP-9、TIMP-1水平，促进肾功能改善，安全可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of Huangkui capsule combined with piperazine ferulate tablets on renal function, oxidative stress, serum matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase inhibitor-1 (TIMP-1) in patients with chronic glomerulonephritis. Methods: 131 patients with chronic glomerulonephritis who were treated in our hospital from April 2019 to January 2021 were selected. The patients were divided into control group (treated with piperazine ferulate tablets) and experimental group (treated with huangkui capsule combined with piperazine ferulate tablets) by two-color ball method. The curative effect, renal function [serum creatinine (Scr), urea nitrogen (BUN), 24-hour urinary protein content (24 h-Upr)], oxidative stress [superoxide dismutase (SOD), malondialdehyde (MDA)] and serum Matrix metalloproteinase-9(MMP-9), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) levels were compared between the two groups, and the incidence of adverse reactions was recorded. Results: Compared with the control group, the total clinical effective rate of the experimental group was significantly higher(P<0.05). Compared with the control group, the Scr, BUN and 24 h-Upr of the experimental group at 3 months after treatment were lower(P<0.05). Compared with the control group, TIMP-1 was lower and MMP-9 was higher of the experimental group at 3 months after treatment(P<0.05). Compared with the control group, MDA of the experimental group at 3 months after treatment was lower and SOD was higher(P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Piperazine ferulate tablets combined with Huangkui capsule in the treatment of patients with chronic glomerulonephritis can reduce oxidative stress, regulate the serum MMP-9 and TIMP-1 levels, and promote the improvement of renal function. It is safe and reliable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
